ABSTRACT
The SARS-CoV-2 exhibits similar aetiology, mode of transmission and clinical presentation as the H1N1pdm09 (a subtype of Influenza A) and Influenza A (other subtypes), and can exist as a coinfection in the same patient. It is essential to understand the coinfection dynamics of these viruses for effective management of the disease. This study examined 959 SARS-CoV-2 positive samples collected from the six states and three union territories in India from May to December 2022. The clinical data was accessed from the Integrated Health Information Platform (IHIP) and the Indian council of medical research (ICMR) COVID-19 data portal. The samples were tested for SARS-CoV-2, H1N1pdm09 and Influenza A using Reverse Transcriptase Real-Time Polymerase Chain Reaction q(RT-PCR). All 959 samples were subjected to SARS-CoV-2 whole genome sequencing (WGS) using Oxford Nanopore Next Generation Sequencing (NGS). From the 959 SARS-CoV-2 positive samples, 17.5% were co-infected with H1N1pdm09, 8.2% were co-infected with Influenza A, and 74.2% were only positive for SARS-CoV-2. The comparative analysis of viral load among the coinfected cases revealed that Influenza A and H1N1pdm09 had higher viral loads than SARS-CoV-2 in the studied samples. Out of 959 samples subjected to WGS, 815 and 144 were considered quality control (QC) passed, and QC failed, respectively, for SARS-CoV-2 variant calling. SARS-CoV-2 WGS identified 46 different variants belonging to the Omicron lineage. The SARS-CoV-2 and Influenza A coinfection group; and the SARS-CoV-2 and H1N1pdm09 coinfection group showed a higher proportion of symptomatic cases. This work demonstrates the need for coinfection analysis for the H1N1pdm09 virus, Influenza A virus and SARS-CoV-2 while studying the etiological agent in individuals with ILI/SARI symptoms. It is recommended that, in addition to determining the aetiology of ILI/SARI, an examination for H1N1pdm09 and Influenza A be conducted concurrently utilising molecular tools such as WGS and RT-PCR to understand the variant dynamics and the viral load for taking an informed decision during the patient management and treatment discourse.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded and supported by the Council of Scientific and Industrial Research - National Environmental Engineering Research Institute, Nagpur
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Council of Scientific and Industrial Research-National Environmental Engineering Research Institute (CSIR-NEERI), Nagpur, India. Institutional Ethics Committee (IEC)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon request
